Notable Runner: It Seems PTC Therapeutics, Inc. Will Go Down. Have Another Big Decline

Notable Runner: It Seems PTC Therapeutics, Inc. Will Go Down. Have Another Big Decline

The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) is a huge mover today! The stock decreased 4.64% or $0.65 during the last trading session, hitting $13.36. About 1.78M shares traded hands or 18.67% up from the average. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 140.72% since March 1, 2016 and is uptrending. It has outperformed by 128.50% the S&P500.
The move comes after 5 months negative chart setup for the $554.52 million company. It was reported on Oct, 4 by Barchart.com. We have $12.69 PT which if reached, will make NASDAQ:PTCT worth $27.73M less.

Analysts await PTC Therapeutics, Inc. (NASDAQ:PTCT) to report earnings on November, 14. They expect $-1.19 EPS, up 6.30% or $0.08 from last year’s $-1.27 per share. After $-1.14 actual EPS reported by PTC Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 4.39% negative EPS growth.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Out of 7 analysts covering PTC Therapeutics (NASDAQ:PTCT), 2 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 29% are positive. PTC Therapeutics has been the topic of 16 analyst reports since July 31, 2015 according to StockzIntelligence Inc. RBC Capital Markets maintained the shares of PTCT in a report on Friday, July 31 with “Outperform” rating. The firm has “Sector Perform” rating by RBC Capital Markets given on Wednesday, February 24. The firm has “Hold” rating given on Wednesday, February 24 by Jefferies. Jefferies downgraded the shares of PTCT in a report on Wednesday, November 25 to “Underperform” rating. As per Friday, October 16, the company rating was maintained by Oppenheimer. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Neutral” rating given on Wednesday, February 24 by Citigroup. As per Friday, October 16, the company rating was maintained by RBC Capital Markets. On Tuesday, July 26 the stock rating was downgraded by Credit Suisse to “Neutral”. On Tuesday, February 23 the stock rating was downgraded by JP Morgan to “Neutral”. The rating was initiated by Citigroup with “Buy” on Tuesday, August 25.

According to Zacks Investment Research, “PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.”

Insitutional Activity: The institutional sentiment increased to 1.23 in 2016 Q2. Its up 0.40, from 0.83 in 2016Q1. The ratio improved, as 17 funds sold all PTC Therapeutics, Inc. shares owned while 30 reduced positions. 17 funds bought stakes while 41 increased positions. They now own 28.13 million shares or 3.23% less from 29.06 million shares in 2016Q1.
Springbok Capital Mngmt holds 0.01% or 8,800 shares in its portfolio. Stonebridge holds 21,385 shares or 0.07% of its portfolio. New York State Common Retirement Fund owns 32,400 shares or 0% of their US portfolio. Rhumbline Advisers last reported 0% of its portfolio in the stock. Voya Invest Management Ltd Liability holds 0% or 14,593 shares in its portfolio. Legal And General Group Incorporated Plc holds 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 8,176 shares. Putnam Invests Ltd Liability, a Massachusetts-based fund reported 220,000 shares. Federated Investors Pa has invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Susquehanna Intl Group Ltd Liability Partnership reported 104,188 shares or 0% of all its holdings. Brandywine Invest Mgmt Limited Co has 0% invested in the company for 56,851 shares. Oppenheimer & holds 87,456 shares or 0.02% of its portfolio. Granite Point Cap Mngmt L P last reported 327,579 shares in the company. Qs Limited Liability Co accumulated 219,206 shares or 0.01% of the stock. Numeric Investors Ltd Llc holds 0.01% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 126,400 shares. State Street Corp has invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT).

More news for PTC Therapeutics, Inc. (NASDAQ:PTCT) were recently published by: Fool.com, which released: “Why PTC Therapeutics, Inc. Gave Back As Much As 10% on Tuesday” on September 20, 2016. Prnewswire.com‘s article titled: “PTC Therapeutics Recognizes World Duchenne Awareness Day by Announcing Winners …” and published on September 07, 2016 is yet another important article.

PTCT Company Profile

PTC Therapeutics, Inc., incorporated on March 31, 1998, is a biopharmaceutical firm focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older in over 30 member states of the European Economic Area (EEA). It holds commercialization rights to Translarna for all indications in all territories, across the world. Translarna is designated as an orphan medicinal product for the treatment of cystic fibrosis (CF), duchenne muscular dystrophy (DMD), Mucopolysaccharidosis type I (MPS I), and aniridia. The Company’s programs include Translarna for nmDMD, Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment